An immunomodulatory and Myotrophic Formulation with Simultaneous Neurotrophic Properties for The Treatment of ALS and Multiple Sclerosis

An Immunomodulatory Formulation consisting of Nf-Kappa B, TNF-A and IL-6 Suppressive protopanaxatriol Class glucopyranoside Analouges, A Neurotrophic Protobioside Analouge that Promotes Myelin Regeneration, A Myotrophic Bioceutical Extract with Partial SARM-Like Effects thus increasing Muscle Mass via Protein Synthesis Enhancement, via GDF-8 Suppression, increasing intramascular MGF and IGF-1 mRNA Expression and Enhancing Cholinergic Neuromascular Transmission Duration. By Inhibiting Pro-Inflammatory Cytokine Release and via increasing Selective Anabolism Formulation Serves as an Effective Adjunctive Treatment for ALS and Multiple Sclerosis. Inventors: Erdal Can Alkoclar Metehan Yesil本免疫调节制剂由可抑制核因子κB(NF-κB)、肿瘤坏死因子α(TNF-α)及白细胞介素6(IL-6)的原人参三醇类吡喃葡萄糖苷类似物、可促进髓鞘再生的神经营养性原糖苷类似物，以及具有部分选择性雄激素受体调节剂(SARM)样作用的肌营养生物药物提取物组成。该肌营养提取物可通过增强蛋白质合成、抑制生长分化因子8(GDF-8)、提升肌内肌源性生长因子(MGF)与胰岛素样生长因子1(IGF-1)的mRNA表达水平，以及延长胆碱能神经肌肉传递时长来增加肌肉质量。本制剂通过抑制促炎细胞因子释放并增强选择性合成代谢，可作为肌萎缩侧索硬化症(ALS)与多发性硬化症的有效辅助治疗方案。发明人：埃尔达尔·坎·阿尔科克拉(Erdal Can Alkoclar)、梅特汉·耶希尔(Metehan Yesil)